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Reduction of Streptococcus pneumoniae in
upper respiratory tract cultures and a
decreased incidence of related acute otitis
media following introduction of childhood
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Abstract
Background: The effect of pneumococcal conjugate vaccines (PCV) on invasive pneumococcal disease is frequently
reported, but the impact on upper respiratory tract infections in a clinical setting is less documented. Our aim in
this 5-year observational study was to investigate serotype changes in a large number of Streptococcus pneumoniae
upper respiratory tract isolates following sequential introduction of PCV7 and pneumococcal Haemophilus influenza
protein D conjugate vaccine (PHiD-CV10) in a Swedish county.
Methods: All bacterial isolates from the upper respiratory tract (nasopharynx, sinus or middle ear fluid) from patients
with respiratory tract infections referred to a clinical microbiology laboratory prior to (2 years 2007–2008; n = 1566) and
after introduction of PCV (3 years 2011–2013; n = 1707) were prospectively collected. Microbiological findings were
compared between the two periods, and information from clinical referrals was recorded in order to explore changes
in incidence of pneumococcal acute otitis media (AOM).
Results: Pneumococcal serotypes covered by PHiD-CV10 decreased from 45 to 12 % prior to and after immunization
(p < 0.001), respectively. Despite non-PHiD-CV10 serotypes increased from 49 to 80 %, a significant decline of 35 % in
the absolute incidence of pneumocococal isolates (p < 0.001) was observed. Finally, the frequency of complicated AOM
caused by S. pneumoniae decreased by 32 % (p < 0.001).
Conclusions: After introduction of PCV in 2009, we have observed a significantly decreased number of pneumococcal
isolates in the upper respiratory tract, a shift to non-PHiD-CV10 serotypes, and a reduction of complicated AOM. Our
findings may have implications for future vaccine design.
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Background
On a global basis, Streptococcus pneumoniae is estimated
to cause 1.6 million fatal infections annually, including
0.7–1 million children aged <5 years. The burden of dis-
ease is highest amongst children <2 years of age and in the
elderly [1]. S. pneumoniae commonly causes invasive dis-
ease (IPD), pneumonia, septicemia and meningitis, but is
also a leading cause of milder non-invasive infections such
as non-bacteremic pneumonia, acute otitis media (AOM)
and sinusitis. Pneumococcal infection is in most cases
preceded by nasopharyngeal colonization.
Despite that more than 90 different pneumococcal sero-
types have been defined, only a minority of them regularly
causes severe infections. In 2001 a conjugated pneumococ-
cal vaccine (PCV) was introduced providing protection
against 7 serotypes (PCV7) and was later replaced by vac-
cines that target either 10 or 13 of serotypes associated
with IPD, but also widespread antimicrobial resistance.
PCV7 included serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F,
whereas the pneumococcal Haemophilus influenzae pro-
tein D conjugate vaccine (PHiD-CV10) includes the add-
itional serotypes 1, 5 and 7F. Finally, PCV13 contains three
more capsule polysaccharides, that is, 3, 6A and 19A.
Prevention of invasive disease in infants [2] in addition to
a herd effect leading to a decreased overall incidence of
IPD in the non-vaccinated population are well-documented
vaccine effects [3, 4]. Moreover, studies have revealed a
protective effect against pneumonia [5], sinusitis in
children [6], and non-invasive vaccine type pneumonia
in adults 65 years of age or older [7]. A consequence of
PCV immunization programmes is, however, replace-
ment of vaccine serotypes with non-vaccine serotypes
in mainly nasopharyngeal carriage in children, but also
in pneumococcal disease [8]. For example, significant
increases of non-vaccine type strains causing IPD offset
the reduction of PCV7 vaccine serotypes in some areas
[9, 10]. Moreover, serotypes colonizing the host are
known to vary geographically and temporally [11, 12],
and PCV efficacy is likely different depending on base-
line serotype distribution. Local surveillance of circula-
ting strains is thus crucial to evaluate impact of PCVs.
PCV7 has been shown to reduce the incidence of
AOM caused by serotypes included in the vaccine, but
evidence of a decrease of all pneumococcal AOM cases
irrespectively of serotype was modest in pre-clinical tri-
als with PCV7 [13]. Importantly, a 34 % reduction in the
overall incidence of AOM was found in a randomized
trial with the 11-valent predecessor to PHiD-CV10 [14].
Post-marketing surveillance of the effect of widespread
immunization of children with PCV7 or PHiD-CV10 have
also demonstrated a substantial decrease in AOM incidence
in non-institutional care and hospitals [15, 16]. However,
some doubts have been brought forward questioning
whether the decline in AOM can be solely attributed to
PCV. Natural variations in AOM incidence, more stringent
diagnostics of AOM to avoid unnecessary prescription of
antibiotics, and variations in influenza epidemiology are
factors that must be considered when determining the
overall efficacy of PCV [17].
The aim of this study was to determine the effects on
incidence of pneumococcal infections and on serotype
replacement after sequential introduction of PCV7 and
PHiD-CV10 in a child immunization programme. We con-
ducted a multiyear observational study investigating the ef-
fects on respiratory tract infections in a well-defined
geographical area. Changes in total pneumococcal preva-




In the southern county of Skåne in Sweden, immunization
with the 7-valent PCV Prevenar® was initiated in January
2009 and was administered on a 2 + 1 schedule at 3, 5
and 12 months of age. It was replaced by PHiD-CV10
(Synflorix®) in June 2010, which was also administered
to children who had received one or two doses of
PCV7. A high coverage was obtained from the start and
among children born in 2009 the coverage was 97.5 %
at 2 years of age [18]. Our study was initiated in 2007
and continued through 2013. We compared 2 years be-
fore (2007/2008) with 3 years after (2011–2013) initi-
ation of the immunization campaign.
Data collection
All clinical isolates of S. pneumoniae from the upper
respiratory tract (from nasopharyngeal swabs, middle ear
fluid and sinuses) identified at the local Clinical micro-
biology lab (Malmö, Sweden) were included. One single,
public clinical microbiology laboratory serves the entire
geographical area. According to regional guidelines, upper
respiratory tract cultures are recommended in patients
with recurrent AOM, treatment failure of AOM,
community-acquired pneumonia (CAP) in adults and
complicated respiratory tract infections, but can also be
obtained in other clinical situations at the discretion of
the referring physician [19]. Routine culturing from naso-
pharynx in adults with suspected pneumonia admitted to
hospital was included in the guidelines in 2009. Bacterial
cultures obtained within a shorter interval than 2 months
from the same patient were excluded.
Study population
Pneumococcal upper respiratory tract isolates (n = 3273)
were obtained from patients in 9 municipalities of the
southwestern Skåne university hospital district. This
catchment area was unchanged during the study years,
while the population increased from 473,245 to 526,092
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inhabitants. Sixty-seven percent were referred from out-
patient clinics and 33 % from hospital infirmaries.
Microbiology
Nasopharyngeal swabs and secretions from sinus and mid-
dle ear were transported to the Clinical microbiology lab in
Amies transport medium with charcoal for culturing within
24 h on CNA agar with sheep blood medium. Pneumococ-
cal isolates were prospectively stored at −80 °C during the
study period. A minority of the isolates (21 %) was not
saved and thus unavailable for serotyping. The numbers of
these missing strains were more or less constant during the
study years and missing isolates were considered as missing
at random (range 19.9-22 %). Bacterial isolates were identi-
fied by standard methods as previously described [20].
Pneumococci were serotyped using a latex agglutination
test and the Neufeld test according to the manufacturer’s
instructions (Statens Seruminstitut, Copenhagen, Denmark)
[21]. Both are capsular reaction tests utilizing anti-
pneumococcal rabbit sera directed against the polysacchar-
ide capsule, and are considered as the “gold standard” for
serotyping of pneumococci [22]. If a negative result was
obtained twice the isolate was designated as “non-type-
able”. No further serotyping was performed if an isolate
was fallen in the non-vaccine serogroups 10 and 35.
Assessment of clinical diagnosis
Patients with a positive pneumococcal culture from the
middle ear fluid, or from the nasopharynx in addition to
concurrent typical symptoms of AOM according to the
description of the referring physicians were identified.
According to current guidelines, which do not recom-
mend culturing on uncomplicated AOM, the identified
AOMs in our material were in most cases complicated.
Data analysis
Descriptive statistics, such as measures of location
and spread was calculated for all variables. We pooled
the pneumococcal upper respiratory tract isolates for
the 2 years prior to (2007/2008) and 3 years after
vaccination (2011–2013), respectively, for comparisons
of absolute and relative incidences. The change in in-
cidence rates (p-values), including 95 % confidence
intervals (CI), after introduction of the vaccine was
calculated using an exact Poisson-test performed in R
version 3.2.1. To assess changes in relative frequen-
cies of PHiD-CV10 vaccine and non-vaccine serotypes
calculations were made with Fischer’s exact test using
IBM SPSS Statistics 21®.
Results
A declining burden of pneumococcal disease
An equal distribution between male and female patients
(49.8 vs. 50.2 %) was observed. The median patient age
at the time of sampling was 3.1 years compared to
4.2 years prior to and after introduction, respectively, of
PCV in the child immunization program. Isolates from
children 2 years or younger became less common be-
tween the observed time periods (Table 1), possibly sug-
gesting a protective effect in the vaccinated population.
The incidence of pneumococcal isolates decreased 35 %
(p < 0.001) from 165 cases per 100,000 inhabitants (95 %
CI: 157–173) pre-PCV to 110 (95 % CI: 104–115) post-
introduction of PCV (Table 1). The annual frequency is
depicted in Fig. 1 and illustrates a continued decline of
pneumococcal isolates from 2011 to 2013. Importantly,
the total number of culture referrals did not change
during the observation period, which suggests that the
number of complicated respiratory tract infections (the
main indication for culturing) remained at a constant
level but that S. pneumoniae as aetiology declined.
In order to detect cases of AOM we analyzed in de-
tail referral texts from samples that were positive for
growth of pneumococci. The physicians ordering bac-
terial cultures provided information on clinical disease
manifestations in 85 % of cases (n = 2782). A signifi-
cant decrease of 32 % (p < 0.001) in frequency of
S. pneumoniae as aetiology for complicated AOM was
found following start of vaccination. The mean annual
frequency was 217 in 2007/2008 and decreased to
147 in 2011–2013.
Serotype replacement of pneumococci
Seventy-nine percent of pneumococcal isolates (n = 2586)
were available for serotyping. Pneumococcal serotypes
covered by PHiD-CV10 were reduced in respiratory tract
infections, and to a large extent replaced by serotypes not
included in the vaccine. In 2007/2008, 45 % of all pneumo-
coccal isolates were covered by PHiD-CV10 compared to
Table 1 Pneumococcal upper respiratory tract isolates analysed
in this study. Incidences from 2 years prior to start of
vaccination are compared to 3 years after PCV introduction
















≤ 2 884 2561 (2392–2730) 744 1250 (1161–1341)
3–16 337 229 (205–254) 330 136 (122–151)
17–40 153 51 (43–59) 234 47 (41–52)
41–64 134 45 (37–53) 265 56 (49–62)
65- 58 34 (26–43) 134 45 (37–52)
All
ages*
1566 165 (157–173) 1707 110 (104–115)
*p <0.001 for difference in incidence ratio between the two time
periods investigated
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12 % in 2011–2013 (Table 2; p < 0.001). In parallel, sero-
types not included in PHiD-CV10 increased from 49 to
80 % (p < 0.001). For example, serotype 11A made up only
4 % of the serotyped pneumococci prior to introduction
of PCV, but emerged as the most common serotype in
2011 (Fig. 2). Four years after PCV initiation, serotype
3 comprised 14 % of the isolates, followed by serotype
19A (11 %) and 23A (8 %). S. pneumoniae serotype 3 is
associated with more severe disease [20], and since no
significant change in the absolute numbers of serotype
3 isolates was observed when the 3 years 2011–2013
were pooled and compared to the pre-vaccine era,
the proportion of serotype 3 isolates among S. pneu-
moniae increased in the post-vaccine period. The
incidence of serotype 6A, which is not included in PHiD-
CV10, decreased significantly (p < 0.001), whereas 6C was
gradually more common. An increased incidence of
pneumococcal serotypes and serogroups 6C, 10, 11A, 15B,
23A, 23B and 35, which are not covered by either of the
currently available vaccines (PHiD-CV10 or PCV13),
was also observed during the study period. Interestingly,
non-vaccine type isolates increased in 2011 compared to
2007/2008 but thereafter the incidence went down in 2012
and 2013 (Fig. 1).
Discussion
We have observed changes in clinical respiratory tract
infections associated with pneumococci after the intro-
duction of PCV in a Swedish County. Bacterial cultures
were referred from a well-defined catchment area served
by a single microbiological laboratory, and a large number
of bacterial samples were compiled during 5 years, allow-
ing comprehensive epidemiological evaluation. Two time
periods, that is, 2 years prior to and 3 years after introduc-
tion of PCV were investigated. Three major findings can
be concluded; i) upper respiratory tract isolates of S. pneu-
moniae decreased by more than a third; ii) a shift in the
distribution of pneumococci from serotypes included in
PHiD-CV10 to non-PHiD-CV10 serotypes; and, finally, iii)
that the frequency of culture-verified S. pneumoniae isolates
in patients with symptoms of AOM decreased significantly.
The efficacy of PCV vaccines on pneumococcal syn-
dromes such as IPD, pneumonia, AOM and sinusitis has
previously been thoroughly investigated [2–7]. Our study
is important since it assesses the impact of PCV on
pneumococci in the upper respiratory tract of all pa-
tients with signs of respiratory infection. These patients
were in our study mainly attending outpatient clinics























Fig. 1 A decreased number of S. pneumoniae was observed during the study period. The total number of referrals for bacterial cultures (both positive
and negative ones) were per year 5886 and 5965 in 2007 and 2008, respectively. During the 3 years 2011–2013 the total numbers of bacterial cultures
were 5908, 5585 and 5647, respectively
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considered. A lower incidence of pneumococcal isolates
may thus reduce the need for antibiotics.
In pre-marketing studies, evidences of any effect of
PCV on AOM are scarce. Our observation of a decrease
in complicated AOM due to S. pneumoniae is, however,
in concordance with several post-licensure studies.
Tamir et al. found a reduction in episodes of severe
pneumococcal AOM [23], and others have reported a
decrease in AOM-related visits to hospitals and out-
patient clinics [17]. The decreased carriage of PCV sero-
types in the population causes a reduced transmission of
pathogenic bacteria, which could explain the decrease in
AOM. It cannot be excluded that other factors, such as
natural variation in AOM disease contributed to the
reduction as presented in our study. Pneumococcal in-
fection is often promoted by influenza virus. However,
according to statistics from the Swedish Public Health
Agency the influenza seasons were of “medium inten-
sity” in 2007/2008 and of “high intensity” in 2011-2013
[24], and thus the observed decrease of pneumococcal
isolates should not be attributed to milder influenza
seasons.
The serotype replacement observed in this study is in
concordance with previous publications [8]. In studies
on carriage of pneumococci in the nasopharynx of chil-
dren, the phenomenon of serotype replacement has been
suggested to maintain overall carriage, even after intro-
duction of PCV [25]. The vacant niche left by eradicated
vaccine serotypes are replaced by non-vaccine strains.
On the other hand, we analysed carriers of pneumococci
having symptoms of respiratory tract infection and not
passive carriage of pneumococci. The observation
that non-vaccine isolates became less prevalent
after introduction of PCV (Fig. 1) might be explained
by a lower virulence among non-PCV serotypes as
previously suggested [8]. Cross-protection of capsule
polysaccharides included in the vaccine could also
have contributed to the overall reduction of clinical
isolates found. Previous results from studies on PCV7
and PHiD-CV10, which both contain the serotype 6B
capsule, have suggested significant cross-reactivity
against serotype 6A, and subsequent protection from
disease caused by this particular serotype [14, 25],
findings that are supported also in the present study.
In contrast, pneumococci carrying the 6C capsule
emerged, and it has recently been recognized as an
expanding serotype in the PCV era.
Pre-marketing studies highlighted cross-protection against
non-vaccine serotype 19A, which is closely related to vac-
cine serotype 19F. However, in some countries with high
PCV7 coverage, an increased pneumococcal disease caused
by serotype 19A has occurred, and questioned the existence
of serotype 19F-19A cross-protection by the PCV7. On the
other hand, PHiD-CV10 has been found to induce higher
anti-19A IgG titers in OPA (opsonophagocytosis) compared
to PCV7, suggesting a superior immune response [26].
Surprisingly, we found that the absolute and relative inci-
dence of S. pneumoniae serotype19A increased during the
observation period, and together with serotype 3 comprised
18.8 % of all S. pneumoniae 4 years after PCV introduction.
Both serotypes 3 and 19A are included in PCV13, which
raised the question of possible benefits for this vaccine in
the study population. However, immunization with serotype
3 has been shown to induce a hyporesponse and the vac-
cine effect against this specific serotype is questioned [27].
Another fact is that PCVs were included in the child
Table 2 Distribution of identified pneumococcal isolates. Two
years (2007/2008) prior to PCV were compared to 3 years after
(2011–2013). Of the total S. pneumoniae included in the present
study, 78.8 % (n = 1234) were available for serotyping prior to and
79.2 % (n = 1352) after PCV introduction. p-values were calculated
for relative incidences. Non-PHiD-CV10 serotypes that represent
less than 2.5 % of serotypes before and after PCV introduction are
grouped as “Others”







1 0.0 (1) 0.0 (0) NA
4 1.8 (22) 0.4 (5) <0.001
5 0.0 (1) 0.0 (0) NA
6B 11.1 (137) 1.6 (21) <0.001
7F 1.5 (19) 0.9 (12) 0.149
9V 1.6 (20) 0.7 (10) 0.043
14 6.4 (79) 1.8 (25) <0.001
18C 2.2 (26) 1.3 (17) 0.093
19F 11.5 (141) 3.1 (42) <0.001
23F 9.1 (112) 2.0 (28) <0.001
Total PHiD-CV10 serotypes 45.2 (558) 11.8 (160) <0.001
3 7.0 (86) 8.8 (119) 0.450
6A 9.1 (112) 3.3 (44) <0.001
6C 2.9 (36) 6.7(91) <0.001
10 0.7 (8) 2.9 (38) <0.001
11A 4.0 (49) 10.0 (135) <0.001
15B 2.1 (26) 9.3 (124) <0.001
19A 3.7 (46) 9.9 (134) <0.001
23A 3.0 (38) 6.4 (87) <0.001
23B 0.3 (4) 4.2 (57) <0.001
35 2.6 (32) 7.4 (100) <0.001
Othersa 13.8 (170) 10.9 (148) 0.111
Total non-PHiD-CV10 serotypes 49.2 (607) 79.7 (1077) <0.001
Non-typeable 5.6 (69) 8.6 (116) <0.001
aOthers were in ascending order: 2, 6D, 7C, 8, 9A, 9N, 11B, 11C, 12, 13, 15A,
15C, 16, 17, 18A, 18B, 18F, 20, 21, 24F, 28, 31, 24, 33, 37, 38, 39, 40, and 42
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immunization programme in order to protect against IPD
in children, whereas the focus of the present study was on
upper respiratory tract isolates. In our catchment area, se-
rotypes 11A and 15B, none of which are included in the
available conjugated vaccines, were among the most com-
mon serotypes after PCV introduction, a finding consist-
ent with previous studies which have also found them to
be emerging pneumococcal serotypes [28, 29].
There are a few limitations associated with our investi-
gation. Firstly, samples may be taken for reasons other
than those recommended by regional guidelines or clin-
ical praxis. Some physicians may also be more prone to
take nasopharyngeal swabs than others. However, we be-
lieve that these confounders are unlikely to have chan-
ged between the two time periods compared. Secondly,
all pneumococcal isolates were not available for typing.
The percentage of lost isolates was, however, evenly dis-
tributed prior to and after the introduction of PCV, and
the missing isolates were considered as missing at
random.
Conclusions
Increased incidence of non-vaccine types may affect vac-
cine efficacy and could have implications for future vaccine
design, i.e., a protein-based vaccine would be ideal with
respect to this. To monitor the frequency of emerging se-
rotypes and highly pathogenic strains such as serotype 3 is
important in the post-PCV era. A related concern is a shift
in disease to other bacterial species, which could poten-
tially offset the positive effects of PCV on airway infections.
This concern regarding upper respiratory tract isolates and
AOM needs to be further investigated.
Abbreviations
AOM, acute otitis media; CI, confidence interval; IPD, invasive pneumoccal
disease; PCV, pneumococcal conjugated vaccine
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Fig. 2 Percental distribution of S. pneumoniae serotypes in the present study. In total, 2586 pneumococci were serotyped. PHiD-CV10 serotypes 1
and 5 are not shown since they were rare (1 isolate each). Non-vaccine serotypes representing less than 2.5 % of isolates were grouped as “Others” and
were, in ascending order, 2, 6D, 7C, 8, 9A, 9 N, 11B, 11C, 12, 13, 15A, 15C, 16, 17, 18A, 18B, 18F, 20, 21, 24F, 28, 31, 24, 33, 37, 38, 39, 40 and 42.
NT = non-typeable pneumococci
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